Key result
Higher coagulation biomarkers link to worse outcomes in elderly AF, but associations vary by OAC.
Why the study?
Incorporating circulating biomarkers into clinical risk assessment tools may improve stroke and systemic embolism risk prediction in AF, yet information on the utility of coagulation biomarkers for risk stratification remains limited.
Answers are grounded in this paper and cite their sources.
Inconsistent biomarker-outcome links in elderly AF on OAC warrant caution for risk stratification; leaves open added value beyond CHA2DS2-VASc.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2023) conducted an editorial in Nonvalvular atrial fibrillation (n=3,194). Coagulation biomarkers (D-dimer, TAT, F1+2, soluble fibrin monomer complex) vs. Lower biomarker levels / OAC vs non-OAC groups was evaluated on Clinical outcomes (stroke/systemic embolism and bleeding). Higher coagulation biomarker levels were associated with poorer outcomes in 3,194 elderly AF patients, though associations were not consistently significant across OAC groups.
Synapse has enriched 10 related papers. Consider them for comparative context: